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A 68-year-old woman with solid/trabecular follicular thyroid carcinoma inside of an autonomously functioning thyroid nodule is
described in this paper. The patient was referred to our clinic for swelling of the neck and an increased pulse rate. Ultrasonography
showed a slightly hypoechoic nodule in the right lobe of the thyroid. Despite suppressed TSH levels, the 99mTc-pertechnetate
scan showed a hot area corresponding to the nodule with a suppressed uptake in the remaining thyroid tissue. Histopathological
examination of the nodule revealed a solid/trabecular follicular thyroid carcinoma. To the best of our knowledge, this is the
ﬁrst case of hyperfunctioning follicular solid/trabecular carcinoma reported in the literature. Even if a hyperfunctioning thyroid
carcinoma is an extremely rare malignancy, careful management is recommended so that a malignancy will not be overlooked in
the hot thyroid nodules.
1.Introduction
Hyperthyroidism due to thyroid carcinoma is an extremely
rarephenomenon.Itiscommonlybelievedthatthediagnosis
of a solitary autonomously functioning thyroid nodule
(AFTN)—a solitary “hot” nodule in radionuclide imaging—
can almost always rule out malignancy in the nodule [1]. In
this paper, we present the rare case of follicular carcinoma
manifesting as an AFTN.
2.CaseReport
A 68-year- old female, aﬀected by a long-standing asymp-
tomatic normally functioning nodule in the right lobe of
the thyroid, developed symptoms of neck swelling and
palpitations. The patient presented a resting pulse rate of
108 and blood pressure of 145/90mmHg. A large pain-
less, well-deﬁned, hard nodule was palpable in the right
lobe of the thyroid; the left lobe was normal, and there
were no cervical lymphadenopathies. Ultrasonography (US)
of the thyroid revealed a large and slightly hypoechoic
nodule (diameters: 33 × 38 × 53mm). Thyroid func-
tion tests showed elevated free triiodothyronine (fT3) of
7.60pmol/L (reference range 2.30–6.30pmol/L) and unde-
tectablethyroid-stimulatinghormone(TSH)of0.006mIU/L
(normal0.4–4.0mIU/L).Thefreethyroxin(fT4)wasnormal
at 11.4pmol/L (reference range 7.5–21.1pmol/L), and both
thyroperoxidase and thyrotropin-receptor autoantibodies
were negative (<60UI/mL and <1U/L, resp.). A
99mTc-
perthechnetate scan demonstrated a large hot area with
inhomogeneous uptake and no cold areas inside corre-
sponding to the nodule, with a suppressed uptake in the
remaining thyroid tissue (Figure 1(a)). Six and 24 hours
radioiodine uptake (RAIU) values were 10% (normal: 5–
15%) and 32% (normal: 10–35%), respectively. The nodule
was considered an AFTN, but radioiodine treatment (that
is the ﬁrst-line treatment for AFTN in our centre) was
ruled-out based on the symptoms (i.e., neck swelling) and
the volume of the nodule. Right loboisthmectomy was
performed (Figure 1(b)) and the histological examination2 Journal of Oncology
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Figure 1:
99mTc scan: hot thyroid nodule in the right thyroid lobe with suppressed extranodular thyroid tissues (a). Surgical specimen from
right lobectomy and isthmectomy (b).
(a) (b)
Figure 2: Hematoxylin/eosin histological stains: follicular carcinoma with solid (a) and solid-trabecular (b) features.
revealed a follicular carcinoma with solid and trabecular
parts and focal signs of angioinvasivity (Figures 2(a), (b)).
The surrounding thyroid tissue showed a follicular architec-
ture with no signs of tumour inﬁltration or spreading. Since
the patient declined further surgery, a radioiodine ablation
was directly performed by administering 131I( 2 . 5 G B q ) .
Serum thyroglobulin was 9.4ng/mL before 131It r e a t m e n t ,
with a corresponding TSH level of 36mUI/L. Six months
after thyroid ablation, a 131I whole-body scanning after
recombinant human TSH administration was negative with
a corresponding undetectable serum Tg (i.e., <0.2ng/mL).
Further followup by clinical examination, including neck US
and Tg measurement, every 6 months, is negative up to now
(3.4 years follow-up).
3. Discussion
Our patient presented with a palpable thyroid nodule and
hyperthyroidism with the absence of TRAb and TPOAb. The
nodule was proved to be functionally autonomous by
99mTc-
pertechnetate imaging and RAIU. However, a follicular
solid/trabecular carcinoma was ﬁnally proved by histological
examination. Hyperthyroidism due to thyroid carcinoma
is a rare, but well-recognized phenomenon. This situation
has been generally described as resulting from excessive
production of thyroid hormone by extensive functioning
metastases, usually from follicular carcinoma [2, 3]. The
incidence of thyroid carcinoma in a hot nodule is reported
to be very low by most authors [4–6], but the incidenceJournal of Oncology 3
is somewhat higher in other retrospective studies [7, 8].
Actually, thyroid carcinoma in a hot nodule has been
described in numerous case reports prior to ours. However,
unlike our case, most of these cases show a cold area within
a hot nodule, indicating that the thyroid carcinoma itself
did not produce thyroid hormone [9]. Women are far more
often aﬀected than men, but no signiﬁcant peak with regard
to age was noted [10]. Interestingly, the histological features
of these tumors correspond in principle to the papillary
carcinoma, as opposed to the metastatic functioning carci-
nomas, essentially being of follicular type [11–15]. Classical
follicular histology is described in the few reported cases of
hyperfunctioning follicular carcinoma while only one case
with a clear-cell variant histotype is described [16–18]. To
the best of our knowledge, we are the ﬁrst to report a case of
hyperfunctioning aggressive follicular carcinoma with solid
and trabecular features. This case underlines the clinical
importance of predicting the incidence of malignancy in hot
thyroid nodules. However, reports in the literature indicate
signiﬁcant diﬃculty in determining the risk that AFTN will
undergo malignant degeneration. Some clinical ﬁndings set
forth the risk factors for malignancy in thyroid nodules:
age <20 or >60 years, male sex, the family history of
diﬀerentiated or medullary thyroid carcinoma or of familial
adenomatous polyposis (Gardner’s syndrome), past history
of head and neck radiation, rapid tumor growth, irregular
outline, ﬁxation to adjacent structures, and symptoms of
tumor invasion [1, 15, 19]. In actual practicei, however, few
patients have these symptoms, and most nodules are nearly
asymptomatic [1]. The classical benign AFTN presents itself
as a smooth, well-deﬁned, round or ovoid mass that moves
freely and occurs in patients aged 40 or over with a history
of long-standing and slowly expanding mass in the neck
[19]. The US pattern, as well as the vascular signals in
power or color-Doppler samplings, is largely overlapped in
malignant nodules and AFTN, as occurred in our patient
[1]. An incomplete suppression of radionuclide uptake in
extranodular thyroid tissues was reported as a risk factor
of malignancy, but this did not occur in our patient
[20]. Diﬀerentiating a benign follicular adenoma from a
malignant follicular carcinoma is challenging by cytology,
and a thyroid scan is advocated in these cases, considering
functioning nodules as being benign [1, 21]. Hot nodules
outside the thyroid can be helpful in diagnosis of malignancy
in the case of metastatic thyroid carcinoma, but this is
rare in practice [22]. In our patient, surgical treatment was
preferred to radioiodine ablation considering her symptoms
and the nodule’s size. However, 131I could be administered
in patients with similar clinical presentation; a progressive
increase in the nodule size after 131I treatment was signalled
as a suspicious sign for malignancy in these cases and
should be promptly evaluated [23]. A possible reason
for why thyroid carcinomas occasionally produce excessive
hormone without extensive metastases could be due to gene
mutations reported to occur in AFTN, including mutations
of G protein α chain gene and TSH-receptor gene with
associated elevated intracellular cAMP [19]. By contrast,
Bourasseauetal.denied TSH-receptorandGproteinαchain
gene mutation in hyperfunctioning thyroid carcinoma [24].
Consequently, further studies are needed to clarify this issue.
The clinical course of a nonmetastatic hyperfunctioning
thyroid carcinoma depends on its histological features and
on the patients’ age and tumor stage at the time of diagnosis
[25]. It seems that the prognosis of metastatic follicular
carcinoma does not diﬀer with the presence or absence
of hyperthyroidism [15, 16, 26]. However, the prognosis
of nonmetastatic hyperfunctioning papillary and follicular
thyroid carcinoma was not fully described in the literature.
In conclusion, our case showed that an aggressive follicular
thyroid carcinoma with solid/trabecular features without
metastases could produce hyperthyroidism, suggesting that
malignancy (even if very rare) cannot always be excluded in
a hot thyroid nodule. Consequently, careful management is
recommended so that malignancy is not overlooked in the
scintigraphically hyperfunctioning nodules.
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